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Abstract
Insulin-like growth factor-1 (IGF-1) is involved in several processes relevant to car-
cinogenesis. We used 416 single-nucleotide polymorphisms robustly associated with 
serum IGF-1 levels to assess the potential causal associations between this hormone 
and site-specific cancers through Mendelian randomization. Summary-level genetic 
association estimates for prostate, breast, ovarian, and lung cancer were obtained 
from large-scale consortia including individuals of European-descent. Furthermore, 
we estimated genetic associations with 14 site-specific cancers in European-descent 
individuals in UK Biobank. Supplementary analyses were conducted for six site-spe-
cific cancers using summary-level data from the BioBank Japan Project. Genetically 
predicted serum IGF-1 levels were associated with colorectal cancer. The odds 
ratio (OR) per standard deviation increase of IGF-1 levels was 1.11 (95% confi-
dence interval [CI] 1.01-1.22; P = .03) in UK Biobank and 1.22 (95% CI 1.09-1.36; 
P = 3.9 × 10−4) in the BioBank Japan Project. For prostate cancer, the corresponding 
OR was 1.10 (95% CI 1.01-1.21; P = .04) in UK Biobank, 1.03 (95% CI 0.97-1.09; 
P = .41) in the prostate cancer consortium, and 1.08 (95% CI 0.95-1.22; P = .24) in 
the BioBank Japan Project. For breast cancer, the corresponding OR was 0.99 (95% 
CI 0.92-1.07; P = .85) in UK Biobank and 1.08 (95% CI 1.02-1.13; P = 4.4 × 10−3) 
in the Breast Cancer Association Consortium. There was no statistically significant 
association between genetically predicted IGF-1 levels and 14 other cancers. This 
study found some support for a causal association between elevated serum IGF-1 
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1 |  INTRODUCTION
Insulin-like growth factor-1 (IGF-1) is involved in several 
processes relevant to carcinogenesis, such as cell prolifera-
tion and apoptosis.1 Acromegaly, which is characterized by 
increased growth hormone levels with concomitant raised 
IGF-1 levels, is associated with higher risk of cancer.2,3 
Moreover observational studies in non-acromegalic popula-
tions have reported that IGF-1 levels are positively associated 
with risk of colorectal,4-6 prostate5,7 and breast cancer,5,8 but 
inversely with risk of ovarian cancer.9 Data on circulating 
IGF-1 levels in relation to other cancers are limited and in-
conclusive.1,5 Considering that circulating IGF-1 levels can 
be altered by diet (particularly by reduced milk and protein 
intake10-14) and medical therapy, establishing the causal asso-
ciation between circulating IGF-1 levels and cancer risk are 
important from a public health and clinical perspective.
Mendelian randomization (MR) is a method to evaluate 
causality by exploiting genetic variants with a strong associa-
tion with the exposure (eg IGF-1 levels) as instrumental vari-
ables to predict the effect of the exposure on disease risk.15 
We used the MR technique to examine the potential causal 
associations between serum IGF-1 levels and site-specific 
cancers.
2 |  MATERIALS AND METHODS
2.1 | Genetic instrument
Single-nucleotide polymorphisms (SNPs) strongly associ-
ated with serum IGF-1 (at P < 5 × 10−8) were taken from 
a genome-wide association study of 358  072 European-
descent participants of UK Biobank.16 After omitting cor-
related SNPs (linkage disequilibrium R2 > 0.01), 416 SNPs 
remained and were used as instrumental variables for IGF-1 
levels (Table S1). The IGF-1 SNPs have been shown to have 
clear enrichment of genome-wide significant signals in core 
genes and pathways related to growth hormone-IGF cascade, 
in particular the upper parts of the cascade that regulate IGF-1 
release, but also downstream components of the cascade sug-
gesting feedback mechanism on IGF-1 levels.17 The vari-
ance in IGF-1 levels explained by the SNPs was 9.4%. The 
F-statistic of the genetic instrument was 80.9. In UK Biobank 
as a whole, serum IGF-1 concentration had a mean value 
of 21.4  nmol/L (standard deviation [SD] 5.7  nmol/L) and 
ranged from 14.2 nmol/L in the first decile to 28.4 nmol/L in 
the ninth decile.
2.2 | Data sources for cancer
Publicly available summary statistics estimates for pros-
tate, breast, ovarian, and lung cancer were obtained, re-
spectively, from the Prostate Cancer Association Group to 
Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) consortium,18 Breast Cancer Association 
Consortium (BCAC),19 Ovarian Cancer Association 
Consortium (OCAC),20 and International Lung Cancer 
Consortium (ILCCO).21 The consortia included participants 
of European ancestry only. We additionally estimated ge-
netic associations with site-specific cancers with at least 1000 
cases (n = 14 cancers) among 367 586 unrelated individuals 
of European ancestry (aged 37-73 years at baseline) in UK 
Biobank. The analyses were conducted using logistic regres-
sion analysis adjusted for age, sex, and ten genetic principal 
components. Cancer ascertainment data was until 31 March 
2017, and outcomes were obtained from the national cancer 
registry, electronic health records, hospital episode statistics 
data, death certification data, and self-reported information 
validated by nurse interview (Table S2). Associations with 
prostate cancer were estimated in men only (n = 168 748) 
and associations with breast, ovarian, uterine, and cervical 
cancer in women only (n = 198 838). UK Biobank was not 
included in any of the consortia. In a supplementary analy-
sis, we used summary statistics data for cancer sites with at 
least 1000 cases (breast cancer data were not available) from 
the BioBank Japan Project.22 Ethical approval to conduct this 
MR analysis based on summary statistics and UK Biobank 
data had been obtained from the Swedish Ethical Review 
Authority.
2.3 | Statistical analysis
The multiplicative random-effects inverse variance 
weighted method was applied for the main analyses.23 
Heterogeneity among estimates derived from individual 
SNPs was assessed using the I2 statistic.24 We have shown 
that genetically predicted IGF-1 levels are robustly related 
levels and increased risk of colorectal cancer. There was inconclusive or no evidence 
of a causal association of IGF-1 levels with prostate, breast, and other cancers.
K E Y W O R D S
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to adult height but not adiposity traits.25 To evaluate the 
direct effect of any observed association between IGF-1 
levels and cancer not mediated via height we used multi-
variable MR analysis.26 Summary statistics estimates for 
height were obtained from UK Biobank (analyses by Neale 
Lab) via the MR-Base platform (http://www.mrbase.org/). 
As sensitivity analyses, we used the weighted median, 
MR-Egger, MR Pleiotropy RESidual Sum and Outlier 
(MR-PRESSO) and contamination mixture methods.23,27-29 
In an additional sensitivity analysis, we excluded self-
reported cancer in UK Biobank. We further conducted 
a sensitivity analysis using the SNP in the IGF1 gene 
(rs11111274), which was strongly associated with IGF-1 
levels (7.59 × 10−175), as genetic instrument. This SNP was 
not available in the PRACTICAL consortium, BCAC, and 
OCAC, but a proxy SNP (rs1520222, in complete linkage 
disequilibrium with rs11111274) was used in the analysis 
based on the PRACTICAL consortium. No suitable proxy 
SNP (linkage disequilibrium R2 > .8) was available in the 
BCAC and OCAC. This variant only explains 0.2% of the 
variance in serum IGF-1. However, as the IGF1 locus is 
the coding region for IGF-1, this analysis has particular 
biological relevance for IGF-1. The analyses were carried 
out using the mrrobust,30 MendelianRandomization,31 and 
MR-PRESSO28 packages. All odds ratios (OR) were ex-
pressed per 1 SD (about 5.7 nmol/L) increment in IGF-1 
levels.
We estimated the power for different cancers using a web 
tool.32 Associations with P values below the Bonferroni-
corrected threshold of <0.0036 (0.05/14 site-specific cancers 
in European-descent individuals) were deemed strong evi-
dence of association, whereas those with P values ranging 
from .0036 and .05 were regarded as suggestive support for a 
possible association.
2.4 | Data availability
Summary-level data from the PRACTICAL consortium,18 
BCAC,19 OCAC,20 ILCCO,21 and BBJ22 are publicly avail-
able. Data from the UK Biobank study are accessible upon 
application (https://www.ukbio bank.ac.uk/).
3 |  RESULTS
3.1 | Statistical power
The power in the analyses of different cancer sites are shown 
in Table S3. We had 80% to 100% power to detect an OR 
of 1.10 (or 0.90) in analyses of cancers of the prostate and 
breast as well as in analyses of ovarian cancer in OCAC. The 
power was 80% or higher at ORs of 1.20 and 1.30 in analyses 
of cancers with 2000 and 1000 cases, respectively, in UK 
Biobank and the BioBank Japan Project.
3.2 | IGF-1 and cancer in European-descent 
individuals
The associations of genetic predisposition to higher 
serum levels of IGF-1 with the 14 site-specific cancers 
in European-descent individuals based on consortia and 
UK Biobank data are shown in Figure 1. There was a sug-
gestive positive association of genetically predicted serum 
IGF-1 levels with colorectal cancer. The OR per SD in-
crease of genetically predicted IGF-1 levels was 1.11 
(95% confidence interval [CI], 1.01-1.22; P  =  .03). For 
prostate cancer, the corresponding OR was 1.10 (95% CI 
1.01-1.21; P = .04) in UK Biobank and 1.03 (95% CI 0.97-
1.09; P = .41) in the PRACTICAL consortium. Genetically 
predicted higher IGF-1 levels was significantly associated 
with higher odds of breast cancer in the BCAC (OR, 1.08; 
95% CI 1.02-1.13; P = 4.4 × 10−3), with similar estimates 
for estrogen-receptor positive (OR, 1.07; 95% CI 1.01-
1.13; P = .02) and estrogen-receptor negative (OR, 1.08; 
95% CI 1.00-1.16; P = .04) breast tumors. However, there 
was no association between genetically predicted IGF-1 
levels and breast cancer in UK Biobank (OR, 0.99; 95% CI 
0.92-1.07; P =  .85). The associations of genetically pre-
dicted IGF-1 levels with cancers of the colorectum, pros-
tate, and breast were similar after adjustment for height 
through multivariable MR analysis (Table S4). There was 
weak or no evidence of association between IGF-1 levels 
and 11 other cancers (Figure 1).
Results were consistent in sensitivity analysis, except for 
suggestive evidence of a positive association between genet-
ically predicted IGF-1 levels and lung cancer in UK Biobank 
in the MR-Egger analysis (Table S5). However, no associa-
tion of IGF-1 levels with lung cancer was observed in other 
sensitivity analyses or in analyses based on the ILCCO data-
set (Table S5). Similar results were observed when excluding 
self-reported cancer in UK Biobank (Figure S1). For exam-
ple, the ORs per SD increase of genetically predicted IGF-1 
levels were 1.13 (95% CI 1.03-1.25; P = .01) for colorectal 
cancer and 1.10 (95% CI 1.00-1.21; P  =  .05) for prostate 
cancer.
In analysis using the SNP in the IGF1 gene as instru-
ment, a suggestive association between genetically pre-
dicted IGF-1 levels and colorectal cancer was observed 
(OR 1.74; 95% CI 1.02-2.97; P =  .04). There was also a 
suggestive association between genetically predicted IGF-1 
levels instrumented by the SNP in the IGF1 gene and pros-
tate cancer, both in the PRACTICAL consortium (OR 1.33; 
95% CI 1.02-1.65; P  =  .01) and UK Biobank (OR 1.67; 
95% CI 1.05-2.65; P = .03). The SNP in the IGF1 gene was 
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not associated with the other site-specific cancers in UK 
Biobank (P > .05).
3.3 | IGF-1 and cancer in Japanese 
individuals
In a supplementary analysis using data from a genome-
wide association study in a Japanese population, genetically 
predicted IGF-1 levels were statistically significantly associ-
ated with colorectal cancer but not prostate, lung, esophageal, 
stomach, or liver cancer (Figure 2). The OR of colorectal can-
cer per SD increase of genetically predicted IGF-1 levels was 
1.22 (95% CI 1.09-1.36; P = 3.9 × 10−4) when using the full 
set of SNPs (Figure 2) and 1.57 (95% CI 1.02-2.41; P = .04) 
when using the SNP in the IGF1 gene. The corresponding 
ORs of prostate cancer were 1.08 (95% CI 0.95-1.22; P = .24) 
(Figure 2) and 0.99 (95% CI 0.60-1.65; P = .98), respectively.
F I G U R E  1  Associations of genetically predicted serum insulin-like growth factor-1 (IGF-1) levels with site-specific cancers in European-
descent individuals. Estimates were derived using the multiplicative random-effects inverse-variance weighted method and were based on up 
to 416 single-nucleotide polymorphisms associated with IGF-1 levels at the genome-wide significance threshold. The I2 value is a measure 
of heterogeneity among estimates from individual single-nucleotide polymorphisms. BCAC, Breast Cancer Association Consortium; ILCCO, 
International Lung Cancer Consortium; OCAC, Ovarian Cancer Association Consortium; PRACTICAL, Prostate Cancer Association Group to 
Investigate Cancer Associated Alterations in the Genome
F I G U R E  2  Associations of genetically predicted serum insulin-like growth factor-1 (IGF-1) levels with site-specific cancers in Japanese 
individuals. Estimates were derived using the multiplicative random-effects inverse-variance weighted method and were based on 336 single-
nucleotide polymorphisms associated with IGF-1 levels at the genome-wide significance threshold and available in the BioBank Japan Project 
genome-wide-association study.22 The I2 value is a measure of heterogeneity among estimates from individual single-nucleotide polymorphisms
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4 |  DISCUSSION
In this MR analysis assessing the potential causal relation 
between serum IGF-1 levels and several cancers, we found 
some evidence that increased IGF-1 levels may increase the 
risk of colorectal cancer. Findings for genetically predicted 
IGF-1 levels in relation to prostate and breast cancer were 
inconsistent with a suggestive positive association observed 
only in UK Biobank (for prostate cancer) or the BCAC (for 
breast cancer), or when using the SNP in the IGF1 gene as 
instrument (for prostate cancer).
Our finding for colorectal cancer confirm those of a pre-
vious MR study which showed an OR of colorectal cancer 
of 1.08 (95% CI 1.03-1.12) per one SD increment of genet-
ically-predicted IGF-1 levels.6 That study further showed 
that directly measured serum IGF-1 levels were associated 
with increased risk of all colorectal tumor subsites, includ-
ing proximal colon, distal colon, and rectal cancer.6 Possible 
mechanisms underlying the increased colorectal cancer risk 
include direct actions of IGF-1 on cell growth or indirect ef-
fects via for example insulin resistance and elevated insulin 
levels.25
The present MR results for IGF-1 and breast cancer based 
on BCAC data are similar to those obtained from another 
MR study also based on BCAC data which showed an OR 
of 1.05 (95% CI 1.01-1.10) per 5 nmol/L increase of genet-
ically predicted IGF-1 levels based on 265 SNPs associ-
ated with serum IGF-1 levels in women.33 Another smaller 
case-control study (4647 cases and 4564 controls) found that 
the IGF-1-increasing allele of rs1520220 in the IGF1 gene 
was associated with higher odds of breast cancer.34 We could 
not replicate an association between genetically predicted 
IGF-1 levels and breast cancer in UK Biobank, potentially 
owing to the lack of power to detect a weak association (41% 
and 93% power to detect an OR of 1.05 and 1.10, respec-
tively), phenotyping differences, or younger participants in 
UK Biobank (eg some current controls in UK Biobank may 
eventually develop cancer later in their life). Given these con-
flicting results, further very large MR studies of IGF-1 levels 
and breast cancer are needed to determine whether there is a 
causal relationship between elevated IGF-1 levels and breast 
cancer risk.
Results of meta-analyses of observational studies have re-
vealed that high IGF-1 levels are associated with an increased 
risk of prostate cancer5,7 and with a lower ovarian cancer 
risk.9 In this MR study of genetically predicted IGF-1 levels 
and risk of prostate and ovarian cancer, results were in the 
same direction as those from observational studies but were 
not statistically significant. However, we found a suggestive 
positive association of genetically predicted IGF-1 levels 
with prostate cancer in UK Biobank (OR 1.10; P = .04) and 
a similar non-significant estimate in the Biobank Japanese 
Project (OR 1.08; P = .24). The reason for the inconsistent 
results might be related to phenotyping differences and dif-
ferent proportions of advanced stage prostate cancer cases 
across datasets.
A strength of this study is the use of several data sources 
of large sample sizes. Moreover we confined the analyses to 
major cancers with at least 1000 cases to ensure sufficient 
power. A limitation is that the genetic associations with 
IGF-1 levels were estimated in UK Biobank from which we 
also obtained genetic association estimates for cancer. This 
may have affected the results in the direction of the obser-
vational association in the analyses of UK Biobank data. 
Nevertheless, given the strong genetic instrument for IGF-1 
levels (F statistic > 10), bias from sample overlap would be 
small.35 Moreover, the association between genetically pre-
dicted IGF-1 levels and colorectal cancer was replicated in 
an independent cohort of Japanese individuals. These sup-
plementary results based on data from the Biobank Japan 
Project should nevertheless be interpreted with caution as 
the genetic variants for serum IGF-1 levels were identified 
in a European population and was not verified in a Japanese 
population. Future investigations using Asian-specific ge-
nome-wide association study estimates for IGF-1 are required 
to obtain more accurate causal estimates for IGF-1 and can-
cer in Asians. Another limitation is that we had insufficient 
power to assess potential non-linear relationships between 
IGF-1 levels and cancer. A further shortcoming is that data 
on advanced stage prostate cancer were not available. Hence, 
more research is necessary to clarify whether IGF-1 plays a 
role in the development of advanced stage prostate cancer.
In conclusion, these MR findings support a potential 
causal association between increased serum IGF-1 levels and 
higher risk of colorectal cancer. There was inconclusive ev-
idence of an association of serum IGF-1 levels with prostate 
and breast cancer, and weak or no evidence for an association 
with other major cancers. These results advocate the current 
clinical practice for colorectal cancer surveillance in patients 
with acromegaly and elevated serum IGF-1 levels.36
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